Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Cancer Cell International
Published in: Cancer Cell International 1/2017

Open Access 01-12-2017 | Primary Research

Identification of genes and pathways potentially related to PHF20 by gene expression profile analysis of glioblastoma U87 cell line

Authors: Tianlong Liu, Tiejun Zhang, Feng Zhou, Jitao Wang, Xiaohu Zhai, Nan Mu, Jongsun Park, Minna Liu, Wenxing Liu, Peijin Shang, Yi Ding, Aidong Wen, Yuwen Li

Published in: Cancer Cell International | Issue 1/2017

Login to get access

Abstract

Background

Glioblastoma is the most common and aggressive brain tumor associated with a poor prognosis. Plant homeodomain finger protein 20 (PHF20) is highly expressed in primary human gliomas and its expression is associated with tumor grade. However, the molecular mechanism by which PHF20 regulates glioblastoma remains poorly understood.

Methods

Genome wide gene expression analysis was performed to identify differentially expressed genes (DEGs) in U87 cells with PHF20 gene knockdown. Gene ontology (GO) and pathway enrichment analyses were performed to investigate the functions and pathways of DEGs. Pathway-net and signal-net analyses were conducted to identify the key genes and pathways related to PHF20.

Results

Expression of 540 genes, including FEN1 and CCL3, were significantly altered upon PHF20 gene silencing. GO analysis results showed that DEGs were significantly enriched in small molecule metabolic and apoptotic processes. Pathway analysis indicated that DEGs were mainly involved in cancer and metabolic pathways. The MAPK, apoptosis and p53 signaling pathways were identified as the hub pathways in the pathway network, while PLCB1, NRAS and PIK3 s were hub genes in the signaling network.

Conclusions

Our findings indicated that PHF20 is a pivotal upstream regulator. It affects the occurrence and development of glioma by regulating a series of tumor-related genes, such as FEN1, CCL3, PLCB1, NRAS and PIK3s, and activation of apoptosis signaling pathways. Therefore, PHF20 might be a novel biomarker for early diagnosis, and a potential target for glioblastoma therapies.
Appendix
Available only for authorised users
Literature
1.
Patrick YW, Santosh K. Malignant gliomas in adults. N Engl J Med. 2008;359:492–507.CrossRef
2.
Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310(17):1842–50.CrossRefPubMed
3.
Ostrom QT, Gittleman H, Fulop J, Liu M, Blanda R, Kromer C, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2008–2012. Neuro-Oncology. 2015;17(suppl 4):v1–62.CrossRef
4.
Badeaux AI, Yang Y, Cardenas K, Vemulapalli V, Chen K, Kusewitt D, Richie E, Li W, Bedford MT. Loss of the methyl lysine effector protein PHF20 impacts the expression of genes regulated by the lysine acetyltransferase MOF. J Biol Chem. 2011;287(1):429–37.CrossRefPubMedPubMedCentral
5.
Li Y, Park J, Piao L, Kong G, Kim Y, Park KA, Zhang T, Hong J, Hur GM, Seok JH, et al. PKB-mediated PHF20 phosphorylation on Ser291 is required for p53 function in DNA damage. Cell Signal. 2013;25(1):74–84.CrossRefPubMed
6.
Zhang T, Park KA, Li Y, Byun HS, Jeon J, Lee Y, Hong JH, Kim JM, Huang SM, Choi SW, et al. PHF20 regulates NF-kappaB signalling by disrupting recruitment of PP2A to p65. Nat Commun. 2013;4:2062.PubMedPubMedCentral
7.
Pallasch CP, Struss A, Munnia A, König J, Steudel W, Fischer U, Meese E. Autoantibodies against GLEA2 and PHF3 in glioblastoma: tumor-associated autoantibodies correlated with prolonged survival. Int J Cancer. 2005;117(3):456–9.CrossRefPubMed
8.
Fischer U, Struss AK, Hemmer D, Pallasch CP, Steudel WI, Meese E. Glioma-expressed antigen 2 (GLEA2): a novel protein that can elicit immune responses in glioblastoma patients and some controls. Clin Exp Immunol. 2001;126(2):206–13.CrossRefPubMedPubMedCentral
9.
Wang Y, Han KJ, Pang XW, Vaughan HA, Qu W, Dong XY, Peng JR, Zhao HT, Rui JA, Leng XS, et al. Large scale identification of human hepatocellular carcinoma-associated antigens by autoantibodies. J Immunol. 2002;169(2):1102–9.CrossRefPubMed
10.
Behrends U, Schneider I, Rossler S, Frauenknecht H, Golbeck A, Lechner B, Eigenstetter G, Zobywalski C, Muller-Weihrich S, Graubner U, et al. Novel tumor antigens identified by autologous antibody screening of childhood medulloblastoma cDNA libraries. Int J Cancer. 2003;106(2):244–51.CrossRefPubMed
11.
Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, et al. Gene ontology: tool for the unification of biology. Nat Genet. 2000;25(1):25–9.CrossRefPubMedPubMedCentral
12.
Dupuy D, Bertin N, Hidalgo CA, Venkatesan K, Tu D, Lee D, Rosenberg J, Svrzikapa N, Blanc A, Carnec A, et al. Genome-scale analysis of in vivo spatiotemporal promoter activity in Caenorhabditis elegans. Nat Biotechnol. 2007;25(6):663–8.CrossRefPubMed
13.
Draghici S, Khatri P, Tarca AL, Amin K, Done A, Voichita C, Georgescu C, Romero R. A systems biology approach for pathway level analysis. Genome Res. 2007;17(10):1537–45.CrossRefPubMedPubMedCentral
14.
Yi M, Horton JD, Cohen JC, Hobbs HH, Stephens RM. Whole pathway scope: a comprehensive pathway-based analysis tool for high-throughput data. BMC Bioinform. 2006;7:30.CrossRef
15.
Kanehisa M, Goto S, Sato Y, Kawashima M, Furumichi M, Tanabe M. Data, information, knowledge and principle: back to metabolism in KEGG. Nucleic Acids Res. 2014;42(D1):D199–205.CrossRefPubMed
16.
Wei Z, Li H. A Markov random field model for network-based analysis of genomic data. Bioinformatics. 2007;23(12):1537–44.CrossRefPubMed
17.
Tang N, Ma L, Lin XY, Zhang Y, Yang DL, Wang EH, Qiu XS. Expression of PHF20 protein contributes to good prognosis of NSCLC and is associated with Bax expression. Int J Clin Exp Pathol. 2015;8(10):12198–206.PubMedPubMedCentral
18.
Taniwaki M, Daigo Y, Ishikawa N, Takano A, Tsunoda T, Yasui W, Inai K, Kohno N, Nakamura Y. Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer. Int J Oncol. 2006;29(3):567–75.PubMed
19.
Nikolova T, Christmann M, Kaina B. FEN1 is overexpressed in testis, lung and brain tumors. Anticancer Res. 2009;29(7):2453–9.PubMed
20.
Ying N, Wang S, Xu H, Wang Y. Association between FEN1 polymorphisms -69G> A and 4150G> T with susceptibility in human disease: a meta-analysis. Iran J Public Health. 2015;44(12):1574–9.PubMedPubMedCentral
21.
Chen Y, Zhang X, Qiu X, Li J, Yuan Q, Jiang T, Yang M. Functional FEN1 genetic variants and haplotypes are associated with glioma risk. J Neuro-Oncol. 2013;111(2):145–51.CrossRef
22.
Xu BJ, An QA, Srinivasa GS, Yan W, Pierce LA, Abel TW, Rush SZ, Cooper MK, Ye F, Shyr Y, et al. Identification of blood protein biomarkers that aid in the clinical assessment of patients with malignant glioma. Int J Oncol. 2012;40(6):1995–2003.PubMed
23.
Pećina-Šlaus N, Gotovac K, Kafka A, Tomas D, Borovečki F. Genetic changes observed in a case of adult pilocytic astrocytoma revealed by array CGH analysis. Mol Cytogenet. 2014;7:95.CrossRefPubMedPubMedCentral
24.
Cui G, Park S, Badeaux AI, Kim D, Lee J, Thompson JR, Yan F, Kaneko S, Yuan Z, Botuyan MV, et al. PHF20 is an effector protein of p53 double lysine methylation that stabilizes and activates p53. Nat Struct Mol Biol. 2012;19(9):916–24.CrossRefPubMedPubMedCentral
25.
Bankovic J, Stojsic J, Jovanovic D, Andjelkovic T, Milinkovic V, Ruzdijic S, Tanic N. Identification of genes associated with non-small-cell lung cancer promotion and progression. Lung Cancer. 2010;67(2):151–9.CrossRefPubMed
26.
Lasho TL, Pardanani A, Tefferi A, Smith DI. Altered expression of tumor suppressor PHF20 in myeloproliferative neoplasms. Leukemia. 2014;28(8):1762–4.CrossRefPubMed
27.
Verstrepen L, Bekaert T, Chau TL, Tavernier J, Chariot A, Beyaert R. TLR-4, IL-1R and TNF-R signaling to NF-κB: variations on a common theme. Cell Mol Life Sci. 2008;65(19):2964–78.CrossRefPubMed
28.
Spyridakis S, Leondaritis G, Nakos G, Lekka ME, Galanopoulou D. A specific phospholipase C activity regulates phosphatidylinositol levels in lung surfactant of patients with acute respiratory distress syndrome. Am J Resp Cell Mol. 2010;42(3):357–62.CrossRef
29.
Kong G, Chang YI, You X, Ranheim EA, Zhou Y, Burd CE, Zhang J. The ability of endogenous Nras oncogenes to initiate leukemia is codon-dependent. Leukemia. 2016;30(9):1935–8.CrossRefPubMedPubMedCentral
30.
Jakob JA, Bassett RL, Ng CS, Curry JL, Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim KB, et al. NRAS mutation status is an independent prognostic factor in metastatic melanoma. Cancer Am Cancer Soc. 2012;118(16):4014–23.
31.
32.
Tsurushima H, Tsuboi K, Yoshii Y, Ohno T, Meguro K, Nose T. Expression of N-ras gene in gliomas. Neurol Med Chir (Tokyo). 1996;36(10):704–8.CrossRefPubMed
33.
Herrero-Gonzalez S, Di Cristofano A. New routes to old places: PIK3R1 and PIK3R2 Join PIK3CA and PTEN as endometrial cancer genes. Cancer Discov. 2011;1(2):106–7.CrossRefPubMed
34.
Kita D, Yonekawa Y, Weller M, Ohgaki H. PIK3CA alterations in primary (de novo) and secondary glioblastomas. Acta Neuropathol. 2007;113(3):295–302.CrossRefPubMed
35.
Li L, Yang XJ. Molecular and functional characterization of histone deacetylase 4 (HDAC4). Methods Mol Biol. 2016;1436:31–45.CrossRefPubMed
36.
Oehme I, Deubzer HE, Wegener D, Pickert D, Linke JP, Hero B, Kopp-Schneider A, Westermann F, Ulrich SM, von Deimling A, et al. Histone deacetylase 8 in neuroblastoma tumorigenesis. Clin Cancer Res. 2009;15(1):91–9.CrossRefPubMed
37.
Zeng LS, Yang XZ, Wen YF, Mail SJ, Wang MH, Zhang MY, Zheng XF, Wang HY. Overexpressed HDAC4 is associated with poor survival and promotes tumor progression in esophageal carcinoma. Aging (Albany NY). 2016;8(6):1236–49.CrossRefPubMedPubMedCentral
38.
Pei Y, Liu K, Wang J, Garancher A, Tao R, Esparza LA, Maier DL, Udaka YT, Murad N, Morrissy S, et al. HDAC and PI3K antagonists cooperate to inhibit growth of MYC-driven medulloblastoma. Cancer Cell. 2016;29(3):311–23.CrossRefPubMedPubMedCentral
Metadata
Title
Identification of genes and pathways potentially related to PHF20 by gene expression profile analysis of glioblastoma U87 cell line
Authors
Tianlong Liu
Tiejun Zhang
Feng Zhou
Jitao Wang
Xiaohu Zhai
Nan Mu
Jongsun Park
Minna Liu
Wenxing Liu
Peijin Shang
Yi Ding
Aidong Wen
Yuwen Li
Publication date
01-12-2017
Publisher
BioMed Central
Published in
Cancer Cell International / Issue 1/2017
Electronic ISSN: 1475-2867
DOI
https://doi.org/10.1186/s12935-017-0459-x

Other articles of this Issue 1/2017

Cancer Cell International 1/2017 Go to the issue

Primary Research

MicroRNA-338-3p suppresses cell proliferation and induces apoptosis of non-small-cell lung cancer by targeting sphingosine kinase 2

Primary Research

Induction of apoptosis and proliferation inhibition of hepatocellular carcinoma by 6-chloro-2-methoxy-N-(phenylmethyl)-9-acridinamine (BA): in vitro and vivo studies

Primary Research

RAC3 influences the chemoresistance of colon cancer cells through autophagy and apoptosis inhibition

Primary Research

MiR-34a and miR-206 act as novel prognostic and therapy biomarkers in cervical cancer

Research article

DMD transcripts in CRL-2061 rhabdomyosarcoma cells show high levels of intron retention by intron-specific PCR amplification

Research

Pleomorphism and drug resistant cancer stem cells are characteristic of aggressive primary meningioma cell lines
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits